June 9 (Reuters) – British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio.
The all-cash deal values Nuvalent at approximately $124 per share, a 40% premium to its last closing price.
(Reporting by DhanushVignesh Babu and Yadarisa Shabong in Bengaluru; Editing by Mrigank Dhaniwala)
Copyright 2026 Thomson Reuters.
Photos You Should See – June 2026
